Skip to content

Health Technology Assessment (HTA) Services

AHTA is an applied research group with national and international reputation in Health Technology Assessment (HTA).

What is HTA?

"The systematic evaluation of the properties and effects of a health technology, addressing the direct and intended effects of this technology, as well as its indirect and unintended consequences, and aimed mainly at informing decision making regarding health technologies.

Note: HTA is conducted by interdisciplinary groups that use explicit analytical frameworks drawing on a variety of methods."

Source: HTA Glossary

What is a Health Technology?

"An intervention developed to prevent, diagnose or treat medical conditions; promote health; provide rehabilitation; or organise healthcare delivery.

Note: The intervention can be a test, device, medicine, procedure, program or system."

Source: HTA Glossary

HTA Services we provide include:

  • Health care evaluation

    AHTA conduct systematic literature reviews and economic modelling to help policy makers know which health care practices are safe, effective and good value-for-money. Health care interventions considered include:

    • Investigational tests for diagnosis, screening, monitoring or staging of diseases;
    • Therapeutic interventions such as surgical procedures or medical devices; or
    • Combinations of tests and interventions (co-dependent technologies). 
    The systematic reviews we produce aim to:

    • Identify all the relevant literature describing studies on a given topic;
    • Appraise the quality of the studies to determine the reliability of the results; and
    • Synthesise the results of the studies to decide whether the health intervention is better or worse for patients than existing alternatives.
    The economic modelling considers all the associated costs, savings, health benefits and harms of the intervention - including long-term consequences - and compares these to current clinical practice. This estimates the overall value-for-money of the intervention. 

    These health care evaluations help to inform Australian Government policy on a variety of topics.
  • Pharmaceutical evaluation

    We critique submissions from industry that are seeking public funding of medicines. The technologies under evaluation include: 

    • Pharmaceuticals
    • Vaccines
    • Co-dependent technologies (i.e. test-drug combintations)
    The following aspects of the technologies are rigorously evaluated:

    • Appropriate clinical place
    • Comparative treatment effect
    • Comparative safety 
    • Cost-effectiveness
    • Predicted use and financial impact on Government budgets

    We also review classes of medicines as part of post-market surveillance activities - examples include a review of statins and of orphan drugs for rare diseases.

  • Horizon scanning

    AHTA write brief assessments of new and emerging technologies in order to inform policy makers about their likely impact on the Australian and New Zealand public health systems. Each technology will have been identified for reasons including, but not limited to:

    • Obvious safety concerns
    • Lack of previous assessment, despite rapid diffusion throughout the health system
    • Clinical impact which is applicable to a large proportion of the population, or to a small proportion of the population, but with obvious and far-reaching benefits. 

    AHTA has an established record of expertise in horizon scanning and has contributed to the International Information Network on New and Emerging Health Technologies. Our activities have assisted in the exchange of information on emerging medical devices, surgical procedures and health care programmes.

  • Disinvestment

    Under the Australian Government's Comprehensive Management Framework for the Medicare Benefits Schedule (MBS), AHTA are contracted to review services that are publicly funded on the MBS to ensure they are safe, effective and appropriately used, and represent value-for-money. The reviews:

    • Are undertaken using an evidence-based process; 
    • Are conducted in consultation with key stakeholders including consumers and medical professionals;
    • Recognise that MBS funding should align with contemporary evidence, ensuring appropriate patient groups receive best clinical practice.   

    Further information is available hereLink to external website.

  • Methodological research

    Our team conduct methodological research that has impacted on the way HTA and clinical practice guideline development is undertaken internationally, including:

    • Methods for evaluating the safety, effectiveness and cost-effectiveness of diagnostic tests;
    • Methods for producing and grading recommendations in evidence-based clinical practice guidelines; and
    • Methods for assessing co-dependent technologies (personalised medicines) and pharmaceuticals for reimbursement decisions. 

    AHTA completed the revision of Guidelines for Industry Submissions to the Pharmaceutical Benefits Advisory Committee. 

  • Guideline development

    AHTA work with professional groups to help develop clinical practice guidelines. AHTA conduct systematic literature reviews to identify best practice in terms of prevention, diagnosis, and treatment of a health issue. Under the National Health and Medical Research Council (NHMRC) process for developing guidelines, the evidence assessment must consider:

    • Evidence base (number and type of studies and their quality)
    • Consistency of the evidence
    • Clinical impact
    • Generalisability of the evidence (does is match the population and clinical setting)
    • Applicability of the evidence (can it be applied to the Australian setting)
    The evidence informs the guidelines, which are then subjected to public and professional scrutiny before being accepted. More information on the NHMRC guidelines process is available hereLink to external website 

  • Ethics Consulting

    Ethics Consulting is available to researchers who want intensive support in thinking through ethical issues. This would be most valuable prior to submitting a Human Research Ethics Committee (HREC) application or after being denied HREC approval.

    Advice would be offered on the following:

    • What are the potential ethical issues?
    • How does the research stand in relation to the National Statement on Ethical Conduct in Human Research?
    • How might the research be better designed to deal with the ethical issues?
    • Does the research need HREC approval?

    This service is led by Dr Drew Carter, Research Fellow (Ethics). Dr Carter has conducted ethics research and teaching in the School of Public Health since 2009 and has led the teaching of ethics to the University's medical students since 2015. He is also a deputy member of the SA Health Human Research Ethics Committee (HREC).

    More information about this service, including a schedule of fees, is available here.

  • Integrated Research Support

    Integrated Research Support is a comprehensive service that includes advice on research fundamentals including research design, methods and ethical issues. Integrated support of this kind is rare. AHTA is well placed to offer it, since AHTA employs experts in ethics, pharmaceutical and health care evaluation, health economics, biostatistics, and data management. It could be especially valuable to researchers designing clinical trials, for example. AHTA can also advise on research involving qualitative and deliberative methods.

    More information about this service is available here. Alternatively, please contact Dr Drew Carter.

For more information about AHTA's services, please email us.

School of Public Health
The University of Adelaide
Address

Mail Drop 545 or 511
Level 9, Adelaide Health & Medical Sciences Building
SA  5005  AUSTRALIA

Contact

T: +61 8 8313 4617
T: +61 8 8313 3576
ahta@adelaide.edu.au

AHTA Logo